Battelle is the world’s largest nonprofit research and development organization, with over 20,000 employees at more than 100 locations globally. Committed to science and technology for the greater good, Battelle is a global research and development organization creating value through innovation for our clients, the nation and the world.

Battelle’s interdisciplinary approach to health and life sciences is solving today’s global health challenges. We leverage decades of experience, world-class facilities and deep science and technology expertise to serve a diverse range of commercial companies, government agencies and university collaborators. Dr. Carol Sabourin is one of eight Senior Research Leaders in a company of over 6,000 scientists and engineers. Under Dr. Carol Sabourin’s leadership, Battelle developed innovative approaches to advancing biodefense vaccines for infectious diseases of high pathogenicity including anthrax, plague, tularemia, and avian influenza. These programs included the development of novel biological assays, approaches to evaluating vaccine efficacy, and statistical modeling. The success of the work has led to numerous multi-million dollar contract and scientific awards from government organizations and biopharmaceutical companies.

Dr. Jessica Winter is an Associate Professor in Chemical and Biomolecular Engineering and Biomedical Engineering at The Ohio State University. She is also a founder, interim CEO, and CSO of Core Quantum Technologies, an OSU University Technology Commercialization Company.

Dr. Winter’s research focuses on the development of nanoparticles for biomedical applications, and CQT is poised to commercialize this work in the imaging, pathology, and drug delivery markets.

Dr. Winter is the author of > 30 papers, 4 provisional patents, 1 full US/PCT patent application, and with her colleagues has raised > $320k in initial start-up funding.

Life Capsules is developing a treatment of deleterious visceral (abdominal) obesity by bioengineered microencapsulated cells dissipating energy in the form of heat (thermogenesis). Unmet medical need: Visceral obesity poses risks for major diseases, such as type 2 diabetes, cardiovascular disease, and some cancers in 90 million Americans. Current anti-obesity therapies include lifestyle interventions, pharmaceuticals, and surgeries; however, efficacy of these therapies on visceral fat (VF) reduction is limited, whereas side effects and obesity relapse are common.

Our innovation: Life Capsules solution for treatment of visceral obesity is based on long-lasting implantations of microencapsulated cells that are engineered to dissipate energy through heat. This therapy was developed by a multidisciplinary Ohio State University (OSU) research team. This product expects to provide low-cost and minimally invasive therapy for visceral obesity in patients that already developed co-morbidities and disabilities and cannot be treated by life style interventions such as diet and exercise. This solution for obesity will address needs of ~37 million obese Americans and lower the $168 billion annual costs of the US medical care system for treatment of obesity-related diseases.

Nationwide Children’s Hospital emergency department is a very busy level one trauma center treating approximately 75,000 patients per year. 1200 of these emergency room visits are trauma alerts.

Historically, documentation of trauma patients was done on paper due to the rapid resuscitation and or stabilization that the patient receives prior to being transferred to the intensive care unit or the operating room; it was thought that it may be too difficult to keep up with the documentation electronically.

With Valerie’s leadership, clinical knowledge and IT skills, she has helped Nationwide Children’s to become one of the first hospitals in the nation to accomplish electronic documentation of real time trauma alerts and become a nationally sought-after program.

OhioHealth is a family of not-for-profit, faith-based hospitals and healthcare organizations. We have been serving patients in Central Ohio since 1891. One of the largest hospital systems in Ohio, we operate with 16,000 associates, 2,400 physicians and 3,000 volunteers.

As we grow, so does our belief that people come first and that all patients deserve the best care available. One way in which OhioHealth fulfills this mission is through the work of our Commercialization program, which is part of a larger innovation initiative that also includes clinical trials and simulation.

Patricia Eisenhardt is a founding manager of OhioHealth’s Commercialization Office. OhioHealth’s end-user driven approach to medical product innovation is rooted in unique, productive business practices that are groundbreaking in medicine. These have led to the launch of 13 new companies and 7 products into clinical use. This success, achieved through a particular blend of business acumen and understanding of technology has a positive impact on the quality of patient care and brings positive attention to our region.

For three decades, Rhonda DeMuth has advanced configuration software to make manufacturing businesses more efficient and diversified, and to create a more engaging experience for the consumer of configure-to-order products.

She has gone beyond the conventional management solutions to lead her company, TDCI, through obstacles that include a leadership and recession crisis, and into period of accelerated growth. In this time when TDCI is sustaining 30% annual revenue growth, she remains accessible to customers who request to talk to her personally, and she is an old-school manager who believes in written performance reviews and incentives to reward employees.

“My primary responsibility is to create the environment where others can succeed.”